Skip to main content

Featured

Tehran Signals Defiance as Supreme Leader Vows Retaliation and Strait Closure

  A man holds a picture of Iran's new supreme leader, Mojtaba Khamenei, while people attend a funeral ceremony for the Iranian military commanders who were killed in strikes, in Tehran Iran’s Supreme Leader issued his first public remarks following the deaths of senior Iranian commanders, vowing that the country will “avenge the martyrs” and maintain the closure of the strategic Strait of Hormuz until what he described as “justice” is served. His comments, delivered during a nationally broadcast address, underscore a sharp escalation in rhetoric at a moment of heightened regional tension. The Supreme Leader framed the recent losses as sacrifices in the defense of Iran’s sovereignty, promising that those responsible “will face consequences.” He also reaffirmed Iran’s decision to keep the Strait closed, a move that has already disrupted global shipping routes and rattled energy markets. The strait, one of the world’s most critical chokepoints for oil transport, has long been a flas...
Post a Comment
Read more

article

Labels

Quebec Declines Coverage for Newly Approved Alzheimer’s Treatment

 

Quebec has announced that it will not cover the cost of lecanemab (Leqembi®), the first disease-modifying Alzheimer’s drug recently approved by Health Canada. The medication, conditionally approved in late October 2025, is designed to slow the progression of early-stage Alzheimer’s disease by targeting amyloid plaques in the brain.

Health Canada’s approval was hailed as a breakthrough, offering hope to patients and families grappling with the devastating effects of dementia. Lecanemab has shown the ability to reduce cognitive decline by about 27% over 18 months in clinical trials. Despite this, Quebec’s public drug insurance plan, administered by the Régie de l’assurance maladie du Québec (RAMQ), has confirmed that the treatment will not be added to its list of covered medications.

The decision raises concerns about accessibility and affordability, as the drug is expected to be costly. While other provinces may still evaluate whether to include lecanemab in their formularies, Quebec’s refusal highlights ongoing debates about the balance between innovation, cost-effectiveness, and equitable access to care.

Advocates, including the Alzheimer Society of Canada, argue that denying coverage could leave many patients without access to a therapy that represents the first real step toward slowing the disease’s progression. Families and healthcare professionals are now calling for further discussions on how Canada’s healthcare system can adapt to emerging treatments that may reshape the future of dementia care.


Labels:

Comments

Post a Comment